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Abstract 
Overview of myelodysplastic/myeloproliferative 
neoplasms detailing clinical, pathologic, 
cytogenetic, and molecular findings. 
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Identity 
This category includes neoplasms which 
demonstrate overlapping clinical, morphologic, and 
genetic features with both myelodysplastic 
syndromes and myeloproliferative neoplasms. Well-
defined entities within this category include chronic 
myelomonocytic leukemia (CMML), atypical 
chronic myeloid leukemia, BCR /ABL1 negative 
(aCML), myelodysplastic/myeloproliferative 
neoplasm with ring sideroblasts and thrombocytosis 
(MDS/MPN-RS-T), and juvenile myelomonocytic 
leukemia (JMML). This category also includes 
myelodysplastic/myeloproliferative neoplasms, 
unclassifiable, which is applied to neoplasms with 
both myelodysplastic and myeloproliferative 
features but which do not fit into any of the 
previously described entities. Cases are excluded 
from this category if WHO criteria are met for 
myelodysplastic syndromes, chronic myelogenous 
leukemia, primary myelofibrosis, polycythemia 
vera, or essential thrombocythemia, and cases with 
PDGFRA, PDGFRB, FGFR1, or PCM1/JAK2. 
Clinics and pathology 
Disease 
Chronic myelomonocytic leukemia (CMML) 
Phenotype/cell stem origin 
Hematopoietic stem cell. 
Epidemiology 
CMML is the most common MDS/MPN, accounting 
for >90% of cases within this category. However, it 
is still relatively rare, with an incidence of 3-
4/1,000,000 person-years (Guru Murthy et al. 2017; 
Srour et al., 2016). There is a slight male 
predominance of 3:1 (Guru Murthy et al. 2017; 
Maynadie et al., 2011). The disease predominantly 
affects patients in their 7th decade of life or later. 
Clinics 
CMML is characterized clinically by fever, 
infection, and hemorrhagic or thrombotic events. 
Patients demonstrate a variable clinical course. In 
some patients a myeloproliferative phenotype 
predominates, characterized by leukocytosis, 
whereas cytopenias are more common in other 
patients with a myelodysplastic phenotype. 
Hepatosplenomegaly is relatively common, 
especially in cases with a myeloproliferative 
phenotype. 
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Pathology 
Diagnosis of CMML requires the presence of a 
persistent peripheral blood monocytosis (>1x109 /L 
or >10%) and less than 20% blasts or blast 
equivalents in the peripheral blood and bone 
marrow. Monoblasts and promonocytes are included 
as blast equivalents. Dysplasia in one or more 
myeloid lineages is a criterion for diagnosis, but in 
its absence a diagnosis of CMML may still be 
rendered if an acquired clonal cytogenetic or 
molecular abnormality is present, the monocytosis 
has persisted for >3 months, and all other causes of 
monocytosis have been excluded (Arber et al. 2016).  
 
CMML is stratified into three prognostic 
categories in the 2016 WHO classification 
based on enumeration of peripheral blood 
and bone marrow blasts and blast equivalents 
(Table 1).  
Table 1. CMML subclassification 
   Blast/Blast Equivalents(%) 
   Peripheral Blood  Bone Marrow 
CMML-0    <2%    <5% 
CMML-1    2-4%    5-9% 
CMML-2    5-19%    10-19% 
Note: The presence of Auer rods in the peripheral 
blood or bone marrow indicates CMML- 
Cytogenetics 
No recurrent cytogenetic abnormalities are identified 
in CMML. 20-40% of cases demonstrate abnormal 
karyotypes, most commonly +8, -Y, and -7/del(7q) 
(Patnaik and Tefferi 2016). 
Genes 
The majority (>90%) of cases of CMML 
demonstrate somatic mutations (Reinig et al., 2016), 
typically in genes encoding epigenetic regulators, 
signalling pathway components, and mRNA splicing 
and transcription machinery. Truncating ASXL1 
mutations have been shown to confer a poor 
prognosis and are included in prognostic schema 
(Patnaik and Tefferi, 2016). The combination of 
concurrent TET2 and SRSF2 mutations has been 
shown to be highly specific for CMML (Malcovati 
et al. 2014; Patnaik and Tefferi 2016). RUNX1, 
NRAS, and CBL are also commonly mutated in 
CMML. 
Treatment 
Allogeneic stem cell transplant is the only curative 
therapy available for CMML. Current therapies have 
not been shown to modify disease course or risk of 
transformation to acute myeloid leukemia (AML). 
Treatment is based on symptom management and 
can include erythropoiesis-stimulating agents, 
hydroxyurea, and hypomethylating agents (Solary 
and Itzykson, 2017). 
Evolution 
15-30% of patients transform to AML per year 
(Solary and Itzykson, 2017; Itzykson et al., 2013). 
Prognosis 
Prognosis is highly variable, with median survival 
ranging from 13-31 months (Schuler et al., 2014). 
Several risk stratification schema incorporating 
clinical, pathologic, and genetic data have been 
proposed. 
Disease 
Atypical chronic myeloid leukemia, BCR-ABL1 
negative (aCML) 
Phenotype/cell stem origin 
Hematopoietic stem cell 
Epidemiology 
aCML is relatively rare, accounting for less than 
10% of cases of MDS/MPN with an incidence rate 
of 0.1/1,000,000 person-years (Guru Murthy et al., 
2017). There is a 2:1 male predominance. 
Clinics 
Patients are typically in their 7th or 8th decades of life 
and present with hepatosplenomegaly, bleeding 
diatheses, or symptoms related to leucocytosis or 
anemia (Dao and Tyner, 2015) 
Pathology 
Diagnosis of aCML requires peripheral blood 
leukocytosis >13x109 /L with >10% immature 
granulocytes and dysgranulopoiesis. Absolute 
monocytosis and basophilia must be absent or 
minimal and a relative monocytosis cannot exist. 
The bone marrow should be hypercellular due to 
granulocytic proliferation with dysplastic features; 
erythroid and megakaryocytic dysplasia may be 
present. Blasts may be increased up to 19% in the 
peripheral blood or bone marrow (Arber et al., 2016). 
Cytogenetics 
No recurrent cytogenetic abnormalities have been 
identified in aCML. 
Genes 
aCML demonstrates a similar spectrum of mutated 
genes as CMML. Up to 30% of cases of aCML 
demonstrate SETBP1 mutations, a frequency much 
higher than in other MDS/MPNs (Meggendorfer et 
al., 2013). ASXL1, NRAS, KRAS, SRSF2, and 
TET2 mutations are common in aCML, whereas 
CSF3R and JAK2 mutations are relatively infrequent 
(<10% of cases) (Meggendorfer et al., 2014). 
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Treatment 
Data to guide therapy is limited and no consensus 
guidelines are available. Allogeneic stem cell 
transplantation is the only curative therapy. 
Hydroxyurea, hypomethylating agents, and 
therapeutics targeted at specific genetic mutations 
may be considered (Gotlib J, 2017). 
Evolution 
A formal subclassification of accelerated disease 
phases is not available. 8 to 40% of cases have been 
reported to transform to AML (Breccia et al., 2006; 
Patnaik et al., 2017). 
Prognosis 
Median survival ranges from 11 to 25 months in 




with ring sideroblasts and thrombocytosis 
(MDS/MPN-RS-T) 
Phenotype/cell stem origin 
Hematopoietic stem cell. 
Epidemiology 
Limited data on the incidence of MDS/MPN-RS-T 
exists, in part due to its recent transition from a 
provisional entity in the 2008 WHO classification to 
a full entity in the 2016 WHO classification (Arber 
et al., 2016). In general, MDS/MPN-RS-T is 
considered rare within MDS/MPNs. 
Clinics 
Patients are typically in their 8th decade of life and 
present with symptoms related to anemia, 
haemorrhage, or thrombosis. Splenomegaly is 
present in a subset of patients (Broseus et al., 2012). 
Pathology 
The diagnosis of MDS/MPN-RS-T requires 
persistent thrombosis (>450x109 /L) in combination 
with anemia with erythroid dysplasia and >15% ring 
sideroblasts. Blasts are required to be less than 1% in 
the peripheral blood and less than 5% in the bone 
marrow. Bone marrow examination should 
demonstrate megakaryocytes with features similar to 
those in primary myelofibrosis or essential 
thrombocytosis; this feature is critical in 
distinguishing MDS/MPN-RS-T from MDS with 
ring sideroblasts. The presence of SF3B1 mutations 
is typical for MDS/MPN-RS-T but not required; in 
the absence of a mutation, the clinical history must 
be interrogated to exclude recent cytotoxic or growth 
factor therapy which may confound morphologic 
interpretation (Arber et al., 2016). 
Cytogenetics 
No recurrent cytogenetic abnormalities have been 
identified in MDS/MPN-RS-T. 
Genes 
Mutations in SF3B1 are frequent in MDS/MPN-RS-
T (>80%). Mutations in JAK2 are also frequent 
(50% of cases) and co-occur with SF3B1 mutations 
(Broseus et al., 2013; Jeromin et al., 2013). MPL and 
CALR mutations are rare. 
Treatment 
Data to guide therapy is limited and no consensus 
guidelines are available. Treatment is aimed at 
symptoms related to anemia and is generally similar 
to treatment for low risk MDS. Patnaik and Tefferi, 
2015 PMID 25899435). 
Evolution 
Transformation to AML is relatively rare (<2%/year) 
(Broseus et al., 2012). 
Prognosis 
Overall median survival has been reported as 6.2 
years in one large series. Importantly, SF3B1 and 
JAK2 mutations has been identified as independent 
risk factors conferring a good prognosis (Broseus et 
al., 2013). 
Disease 
Juvenile myelomonocytic leukemia (JMML) 
Phenotype/cell stem origin 
Hematopoietic stem cell 
Epidemiology 
JMML typically occurs in young children, with the 
majority of cases being diagnosed before 3 years of 
age. The incidence is 1.3/1,000,000 person-years in 
children under the age of 15 (Hasle H, 1994). There 
is a 2:1 male predominance (Emanuel PD, 2008). 
Clinics 
Patients typically present with fevers and failure to 
thrive. Physical exam commonly demonstrates 
hepatosplenomegaly, lymphadenopathy, and/or 
rash. Patients with type 1 neurofibromatosis show 
typical findings of this syndrome. 
Pathology 
Diagnosis of JMML requires the presence of 
peripheral monocytosis (>1x109 /L), <20% blasts in 
blood or bone marrow, and splenomegaly. In 
addition, one of the following genetic findings is 
required: somatic mutations in PTPN11, KRAS, or 
NRAS; germline NF1 mutation or clinical diagnosis 
of type 1 neurofibromatosis; germline CBL mutation 
or loss of heterozygosity. In the absence of any of 
these genetic findings, the diagnosis may still be 
rendered if monosomy 7 or any other chromosomal 
abnormality is present and one the following four 
criteria are fulfilled: haemoglobin F increased for 
age; myeloid or erythroid precursors identified on 
the peripheral blood smear; GM-CSF 
hypersensitivity in colony assay; or 
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hyperphosphorylation of STAT5 (Arber et al., 
2016). 
Cytogenetics 
Partial or complete loss of chromosome 7 (Note: see 
also Familial monosomy 7 syndrome) occurs in 25% 
of cases (Emanuel PD, 2008; Luna-Fineman et al., 
1995). 
Genes 
Activating mutations in the RAS signalling pathway 
are present in 85-90% of cases. Specifically, in order 
of decreasing frequency, the following genes show 
somatic or germline mutations: PTPN11, NRAS, 
KRAS, CBL, and NF1 (Loh M et al., 2004; Tartaglia 
M et al., 2003). 
Treatment 
Allogeneic stem cell transplantation is the primary 
treatment modality (Locatelli and Niemeyer, 2015). 
Optimal pre-transplant conditioning regimens are 
currently the subject of ongoing clinical trials. 
Evolution 
Transformation to AML occurs in 10-15% of cases. 
Prognosis 
The clinical course of JMML is variable and is 
partially dependent on the underlying molecular 
lesion. The majority of cases demonstrate a 
progressive clinical course. However, patients with 
germline CBL mutations show spontaneous 
remission (Locatelli and Niemeyer, 2015; Dvorak 




This entity is included under MDS/MPN to include 
rare cases which demonstrate both myelodysplastic 
and myeloproliferative clinicopathologic features, 
but which do not fulfil criteria for any other entities 
within the MDS/MPN category. 
Genes involved and 
proteins 
Note 
ASXL1, CALR, CBL, CSF3R, JAK2, KRAS, MPL, 
NF1, NRAS, PTPN11, RUNX1, SETBP1, SF3B1, 
SRSF2, TET2. 
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